Pancytopenia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: PNC001 MIFTS: 54	Pancytopenia Categories: Blood diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Pancytopenia

MalaCards integrated aliases for Pancytopenia:

Name: Pancytopenia ¹² ²⁹ ⁵⁴ ⁶ ⁴³ ¹⁵ ⁷¹

Classifications:

MalaCards categories:
Anatomical: Blood diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:12450

ICD9CM ³⁴ 284.1

MeSH ⁴³ D010198

NCIt ⁴⁹ C34889 C80693

ICD10 ³² D61.81

UMLS ⁷¹ C0030312

Sources

Summaries for Pancytopenia

Disease Ontology : ¹² An anemia that is characterized by a reduction in the number of red blood cells, white blood cells, and platelets.

MalaCards based summary : Pancytopenia is related to amegakaryocytic thrombocytopenia, congenital and diamond-blackfan anemia. An important gene associated with Pancytopenia is DNAJC21 (DnaJ Heat Shock Protein Family (Hsp40) Member C21), and among its related pathways/superpathways are Folate Metabolism and Immune response IFN alpha/beta signaling pathway. The drugs Prednisone and Oprelvekin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : ⁷⁴ Pancytopenia is a medical condition in which there is a reduction in the number of red and white blood... more...

Sources

Related Diseases for Pancytopenia

Diseases related to Pancytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 756)

#	Related Disease	Score	Top Affiliating Genes
1	amegakaryocytic thrombocytopenia, congenital	33.5	THPO MPL DKC1
2	diamond-blackfan anemia	32.8	TP53 THPO MPL EPO DNAJC21 DKC1
3	aplastic anemia	32.6	TPMT TP53 THPO TERT SH2D1A MPL
4	neutropenia	31.7	TPMT THPO MPL EPO CSF3 CSF2
5	thrombocytopenia	31.6	THPO MPL MGMT IFNG FOXP3 EPO
6	miliary tuberculosis	31.5	IFNG EPO CSF3
7	hypersplenism	31.5	THPO IFNG FOXP3 EPO CSF3 CSF2
8	granulocytopenia	31.5	CSF3 CSF2 CP
9	myelofibrosis	31.4	TP53 THPO MPL EPO CSF3
10	deficiency anemia	31.3	TTR THPO MPL FOXP3 EPO CSF3
11	leukemia, acute lymphoblastic	31.3	TPMT THPO MPL DHFR CSF3 CSF2
12	hemoglobinuria	31.3	THPO MPL EPO CSF3
13	iron metabolism disease	31.3	TTR EPO CP
14	diarrhea	31.3	TTR IFNG FOXP3 CSF3
15	myelodysplastic syndrome	31.3	TP53 THPO TERT SAMD9L MPL MGMT
16	dyskeratosis congenita	31.2	TP53 TERT EPO DNAJC21 DKC1 CSF3
17	acquired immunodeficiency syndrome	31.2	TP53 IFNG EPO CSF2
18	rheumatoid arthritis	31.2	TTR SH2D1A IFNG FOXP3 CSF2 CSF1
19	arthritis	31.1	IFNG FOXP3 CSF2 CSF1 CPT2
20	refractory anemia	31.1	MPL EPO CSF3
21	mucositis	31.1	CSF3 CSF2 CSF1
22	aspergillosis	31.1	IFNG CSF3 CSF2 CSF1
23	iron deficiency anemia	31.0	THPO EPO CP
24	malaria	31.0	TTR TP53 IFNG FOXP3 EPO DHFR
25	thrombocytosis	30.9	THPO MPL EPO CSF3 CSF2
26	leukemia, acute myeloid	30.9	TP53 THPO TERT SAMD9L MPL EPO
27	acute radiation syndrome	30.8	EPO CSF3
28	myeloma, multiple	30.8	TTR TP53 IFNG FOXP3 EPO CSF3
29	shwachman-diamond syndrome 1	30.8	DNAJC21 DKC1 CSF3
30	polycythemia	30.8	THPO MPL EPO
31	pneumonia	30.8	TTR IFNG FOXP3 DHFR CSF3 CSF2
32	severe combined immunodeficiency	30.7	IFNG DKC1 CSF3 CSF2 CSF1
33	gastroenteritis	30.7	IFNG CSF3 CSF2 CP
34	stomatitis	30.7	IFNG CSF3 CSF2
35	polycythemia vera	30.7	THPO MPL EPO CSF3 CSF2
36	lung disease	30.7	TP53 TERT IFNG CSF3 CSF2
37	leukemia, chronic myeloid	30.6	TP53 THPO MPL EPO CSF3 CSF2
38	granulosa cell tumor of the ovary	30.6	TP53 TERT CP
39	monocytic leukemia	30.6	IFNG CSF2 CSF1
40	mucormycosis	30.6	IFNG CSF3 CSF2
41	myeloproliferative neoplasm	30.5	THPO MPL EPO CSF3 CSF2
42	cyclic neutropenia	30.5	IFNG CSF3 CSF2 CSF1
43	interstitial lung disease	30.5	TERT IFNG FOXP3 CSF2
44	childhood leukemia	30.5	TP53 DHFR CSF3
45	splenic sequestration	30.4	THPO MPL EPO
46	leprosy 3	30.4	IFNG FOXP3 CSF2
47	chronic myelomonocytic leukemia	30.4	TP53 MPL CSF3 CSF2 CSF1
48	gastric adenocarcinoma	30.3	TP53 TERT MGMT IFNG FOXP3
49	severe congenital neutropenia	30.3	CSF3 CSF2 CSF1
50	hydrocephalus	30.3	TTR TP53 IFNG EPO

Graphical network of the top 20 diseases related to Pancytopenia:

Sources

Symptoms & Phenotypes for Pancytopenia

MGI Mouse Phenotypes related to Pancytopenia:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.43	CP CPT2 CSF1 CSF2 DHFR DKC1
2	hematopoietic system	MP:0005397	10.38	CP CSF1 CSF2 CSF3 DHFR DKC1
3	immune system	MP:0005387	10.34	CP CPT2 CSF1 CSF2 CSF3 DHFR
4	cellular	MP:0005384	10.24	CP CSF1 CSF2 DHFR DKC1 EPO
5	cardiovascular system	MP:0005385	10.21	CP CPT2 CSF1 CSF2 DHFR EPO
6	mortality/aging	MP:0010768	10.2	CPT2 CSF1 CSF2 DHFR DKC1 DNAJC21
7	integument	MP:0010771	10.1	CSF1 CSF2 CSF3 DHFR DKC1 EPO
8	liver/biliary system	MP:0005370	9.97	CP CSF1 DHFR EPO FOXP3 IFNG
9	neoplasm	MP:0002006	9.8	CSF2 DKC1 IFNG MGMT SAMD9L TERT
10	no phenotypic analysis	MP:0003012	9.7	CSF1 DKC1 FOXP3 IFNG MGMT TP53
11	renal/urinary system	MP:0005367	9.5	CSF2 CSF3 DKC1 FOXP3 IFNG TP53
12	respiratory system	MP:0005388	9.32	CPT2 CSF1 CSF2 DKC1 EPO FOXP3

Sources

Drugs & Therapeutics for Pancytopenia

Drugs for Pancytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Oprelvekin

Approved, Investigational

Phase 4

145941-26-0

Antilymphocyte Serum

Phase 4

Nandrolone decanoate

Approved, Illicit

Phase 3

360-70-3

9677

Nandrolone phenpropionate

Approved, Illicit, Investigational

Phase 3

62-90-8

229455

Miconazole

Approved, Investigational, Vet_approved

Phase 2, Phase 3

22916-47-8

4189

Vidarabine

Approved, Investigational

Phase 2, Phase 3

24356-66-9

32326 21704

Nandrolone

Experimental, Investigational

Phase 3

434-22-0

9904

Thymoglobulin

Phase 3

Hormone Antagonists

Phase 3

Anabolic Agents

Phase 3

Androgens

Phase 3

Hormones

Phase 3

Antirheumatic Agents

Phase 2, Phase 3

Immunosuppressive Agents

Phase 2, Phase 3

Anti-Infective Agents

Phase 2, Phase 3

Cyclosporins

Phase 2, Phase 3

Antifungal Agents

Phase 2, Phase 3

Calcineurin Inhibitors

Phase 2, Phase 3

Alkylating Agents

Phase 2, Phase 3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

5743

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

6741

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

5755

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Idarubicin

Approved

Phase 2

58957-92-9

42890

Cytarabine

Approved, Experimental, Investigational

Phase 2

147-94-4, 65-46-3

6253

Danazol

Approved

Phase 1, Phase 2

17230-88-5

28417

Busulfan

Approved, Investigational

Phase 2

55-98-1

2478

Tacrolimus

Approved, Investigational

Phase 2

104987-11-3

445643 439492 6473866

Mycophenolic acid

Approved

Phase 2

24280-93-1

446541

Abatacept

Approved

Phase 1, Phase 2

332348-12-6

10237

Hydroxyurea

Approved

Phase 1, Phase 2

127-07-1

3657

Melphalan

Approved

Phase 1, Phase 2

148-82-3

4053 460612

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030 46835353

Everolimus

Approved

Phase 2

159351-69-6

6442177 70789204

Mesna

Approved, Investigational

Phase 2

3375-50-6

598

rituximab

Approved

Phase 1, Phase 2

174722-31-7

10201696

alemtuzumab

Approved, Investigational

Phase 2

216503-57-0

tannic acid

Approved

Phase 2

1401-55-4

Benzocaine

Approved, Investigational

Phase 2

1994-09-7, 94-09-7

2337

Lenalidomide

Approved

Phase 1, Phase 2

191732-72-6

216326

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Sargramostim

Approved, Investigational

Phase 2

123774-72-1, 83869-56-1

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Tegafur

Approved, Investigational

Phase 2

17902-23-7

5386

Interventional clinical trials:

(show top 50) (show all 118)

#	Name	Status	NCT ID	Phase	Drugs
1	Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia	Unknown status	NCT01997372	Phase 4	ATG
2	Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia	Completed	NCT02314273	Phase 4	rhIL-11
3	Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia	Recruiting	NCT03243656	Phase 4	Eltrombopag
4	Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases	Unknown status	NCT01019876	Phase 2, Phase 3	Fludarabine;Cyclophosphamide;Cyclophosphamide 40;Cyclophosphamide 30
5	The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population	Unknown status	NCT02393508	Phase 3
6	Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders	Completed	NCT00000597	Phase 3	antilymphocyte serum;nandrolone
7	Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders	Completed	NCT00176878	Phase 2, Phase 3	Fludarabine monophosphate;Busulfan
8	Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome	Completed	NCT00774527	Phase 3	Cyclophosphamide-fludarabine-anti thymocyte globulin
9	Outcome of Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin (ATG ) Conditioning Regimens in Severe Aplastic Anemia Patients	Not yet recruiting	NCT03295058	Phase 2, Phase 3	Non ATG Conditioning regimen;GVHD Prophylaxis;ATG conditioning regimen
10	Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria	Unknown status	NCT01642979	Phase 2	Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
11	Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)	Unknown status	NCT01760096	Phase 2	Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
12	A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia	Unknown status	NCT02203396	Phase 2	rabbit ATG, Cyclosporine, Levamisole
13	Male Hormones for Telomere Related Diseases	Unknown status	NCT02055456	Phase 1, Phase 2	Nandrolone Decanoate
14	Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study	Unknown status	NCT02781155	Phase 1, Phase 2
15	PhaseⅠ/ⅡTrial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia.	Unknown status	NCT01305694	Phase 1, Phase 2
16	PhaseⅡTrial of Co-transplantation With Bone Marrow Derived Mesenchymal Stem Cells From Related Donors in Alternative Donor Transplantation of Severe Aplastic Anemia.	Unknown status	NCT02247973	Phase 2
17	Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation	Unknown status	NCT01757145	Phase 2	Eltrombopag
18	A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment	Completed	NCT00065260	Phase 2	Campath-1H;r-ATG;CsA
19	A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab	Completed	NCT00260689	Phase 2	Cyclosporine;Alemtuzumab
20	Doxil® (Pegylated Liposomal Doxorubicin), Dexamethasone Plus Thalidomide (Ddt) in Previously Untreated Multiple Myeloma: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life	Completed	NCT00222105	Phase 2	Doxil;Thalidomide;Dexamethasone
21	A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia	Completed	NCT00061360	Phase 2	ATG+Rapamune+cyclosporine;ATG+cyclosporine
22	Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells	Completed	NCT02277639	Phase 2
23	Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia	Completed	NCT01193283	Phase 1, Phase 2	Cyclophosphamide;Cyclosporine
24	HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY	Completed	NCT00731328	Phase 2
25	Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes	Completed	NCT00004143	Phase 2	Campath, Chemo and/or TBI Allo SCT
26	Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation	Completed	NCT02337595	Phase 1, Phase 2
27	A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy	Completed	NCT02404025	Phase 2	Eltrombopag;Rabbit ATG;CsA
28	A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia	Completed	NCT02148133	Phase 2	Eltrombopag 12.5 mg;Eltrombopag 25 mg
29	Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series	Completed	NCT00392951	Phase 1, Phase 2	sirolimus
30	Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study	Completed	NCT00077116	Phase 2	busulfan;cyclophosphamide;cytarabine;gemtuzumab ozogamicin;idarubicin
31	A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia	Completed	NCT02302469	Phase 1, Phase 2	Revlimid
32	CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease	Completed	NCT01049854	Phase 2	Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
33	A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia	Completed	NCT01187017	Phase 1, Phase 2	Cyclophosphamide;Fludarabine
34	Male Hormones for Telomere Related Diseases	Completed	NCT01441037	Phase 1, Phase 2	Danazol
35	A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)	Completed	NCT00072969	Phase 2	Daclizumab
36	A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA)	Completed	NCT00005935	Phase 2	Mycophenolate mofetil;Cyclosporine
37	A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS)	Completed	NCT00217594	Phase 2	Alemtuzumab (Campath)
38	Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment	Completed	NCT00944749	Phase 2	h-ATG (ATGAM );Cyclosporine (Gengraf )
39	AMD3100 in Combination With G-CSF to Mobilize Peripheral Blood Stem Cells in Patients With Fanconi Anemia(FA): A Phase I/II Study	Completed	NCT00479115	Phase 1, Phase 2	AMD3100
40	Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)	Completed	NCT00326417	Phase 1, Phase 2	Fludarabine;Cyclophosphamide 150mg;Cyclophosphamide 100mg;Cyclophosphamide 50mg
41	A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia	Recruiting	NCT02833805	Phase 2	Thymoglobulin;Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
42	Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases	Recruiting	NCT03314974	Phase 2
43	A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders	Recruiting	NCT03128996	Phase 1, Phase 2	RIC regimen;GVHD prophylaxis regimen
44	PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders	Recruiting	NCT03513328	Phase 1, Phase 2	Thiotepa--single daily dose;Thiotepa--escalated dose
45	A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor	Recruiting	NCT02828592	Phase 2	Fludarabine;Cyclophosphamide;Rabbit ATG;Cyclophosphamide
46	A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes	Recruiting	NCT02224872	Phase 2	Thymoglobulin;Fludarabine;Cyclophosphamide;Mesna;Tacrolimus;Mycophenolic acid mofetil
47	Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation	Recruiting	NCT03622788	Phase 1, Phase 2	Cyclophosphamide;Fludarabine
48	Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure	Recruiting	NCT03500731	Phase 1, Phase 2	Rituximab;Alemtuzumab;Fludarabine;Thiotepa;G-CSF;Hydroxyurea
49	Clinical Phase II Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Paediatric Patients With Non-malignant Diseases	Recruiting	NCT02349906	Phase 2	Treosulfan;Busilvex
50	Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen	Recruiting	NCT02722668	Phase 2	Fludarabine;Cyclophosphamide;MMF;Sirolimus

Search NIH Clinical Center for Pancytopenia

Cochrane evidence based reviews: pancytopenia

Sources

Genetic Tests for Pancytopenia

Genetic tests related to Pancytopenia:

#	Genetic test	Affiliating Genes
1	Pancytopenia ²⁹

Sources

Anatomical Context for Pancytopenia

MalaCards organs/tissues related to Pancytopenia:

⁴⁰

Bone, Bone Marrow, T Cells, Myeloid, Liver, B Cells, Kidney

Sources

Publications for Pancytopenia

Articles related to Pancytopenia:

(show top 50) (show all 6804)

#	Title	Authors	PMID	Year
1	Perioperative management for a patient with chronic pancytopenia: a case of aplastic anemia with persistent neutropenia following preoperative administration of G-CSF. ⁵⁴ ⁶¹	Nakano Y...Okutani R	20094735	2010
2	[Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen]. ⁵⁴ ⁶¹	Nakazato T...Kakimoto T	20379108	2010
3	Massive ascites associated with all-trans retinoic acid treatment in therapy-related acute promyelocytic leukemia. ⁵⁴ ⁶¹	Suzukawa M...Shinohara K	20190483	2010
4	Development of thrombopoietin receptor agonists for clinical use. ⁵⁴ ⁶¹	Ikeda Y...Miyakawa Y	19630808	2009
5	Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. ⁵⁴ ⁶¹	Nagane M...Shiokawa Y	19037596	2009
6	Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. ⁵⁴ ⁶¹	Krishnan C...Kerr DA	18541787	2008
7	Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. ⁵⁴ ⁶¹	de Boer NK...van Kuilenburg AB	18520612	2008
8	Acute colchicine intoxication in a child: a case report. ⁵⁴ ⁶¹	Bicer S...Uzel N	17505274	2007
9	[Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy]. ⁵⁴ ⁶¹	Tadokoro J...Mitani K	17313078	2007
10	Donor-type myelodysplastic syndrome with t(2;3) and monosomy 7 after allogeneic peripheral blood stem cell transplantation and liver transplantation in a patient with severe-type aplastic anemia. ⁵⁴ ⁶¹	Hashino S...Asaka M	17118765	2006
11	Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine. ⁵⁴ ⁶¹	Gardiner SJ...Begg EJ	16995868	2006
12	MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. ⁵⁴ ⁶¹	Germeshausen M...Welte K	16470591	2006
13	Thrombopoietin regulates differentiation of rhesus monkey embryonic stem cells to hematopoietic cells. ⁵⁴ ⁶¹	Wang Z...Welte K	15958695	2005
14	[CD5- CD11c+ CD23- small lymphocytic lymphoma evolving from aplastic anemia]. ⁵⁴ ⁶¹	Kikuchi M...Ueda R	15387287	2004
15	[Spontaneous recovery from pancytopenia in a young female patient with paroxysmal nocturnal hemoglobinuria(PNH): changes in the GPI-anchor expression on peripheral blood cells]. ⁵⁴ ⁶¹	Inukai T...Nakazawa S	15103939	2004
16	Refractory chronic GVHD emerging after splenectomy in a marrow transplant recipient with accelerated phase CML. ⁵⁴ ⁶¹	Rodrigues CA...de Oliveira JS	12858207	2003
17	Co-administration of Flt-3 ligand counteracts the actions of thrombopoietin in myelosuppressed rhesus monkeys. ⁵⁴ ⁶¹	Hartong SC...Wagemaker G	12694260	2003
18	Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. ⁵⁴ ⁶¹	Kaskas BA...Schwab M	12477776	2003
19	Adult purpura fulminans associated with staphylococcal infection and administration of colony-stimulating factors. ⁵⁴ ⁶¹	Galimberti R...Kowalczuk A	12609794	2003
20	Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease. ⁵⁴ ⁶¹	Rosen R...Bousvaros A	12454589	2002
21	Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. ⁵⁴ ⁶¹	Schwab M...Kaskas BA	12172211	2002
22	Girl with combined cellular immunodeficiency, pancytopenia, malformations, deletion 11q23.3 --> qter, and trisomy 8q24.3 --> qter. ⁵⁴ ⁶¹	Ounap K...Laidre P	11920839	2002
23	Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. ⁵⁴ ⁶¹	Basser RL...Begley CG	11895799	2002
24	[Successful combined therapy with ATG, cyclosporin and G-CSF for both liver dysfunction and bone marrow failure in hepatitis-associated aplastic anemia]. ⁵⁴ ⁶¹	Adachi Y...Urabe A	11680980	2001
25	Colchicine induced toxicity and pancytopenia at usual doses and treatment with granulocyte colony-stimulating factor. ⁵⁴ ⁶¹	Yoon KH	11361215	2001
26	Early onset methotrexate-induced pancytopenia and response to G-CSF: a report of two cases. ⁵⁴ ⁶¹	Yoon KH...Ng SC	17039083	2001
27	c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. ⁵⁴ ⁶¹	Ballmaier M...Welte K	11133753	2001
28	One novel and two recurrent missense DKC1 mutations in patients with dyskeratosis congenita (DKC). ⁵⁴ ⁶¹	Heiss NS...Poustka A	11491307	2001
29	Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency. ⁵⁴ ⁶¹	McBride KL...Szumlanski CL	11037857	2000
30	[Two cases of intravascular lymphomatosis diagnosed antemortem by transbronchial lung biopsy]. ⁵⁴ ⁶¹	Taura Y...Katou T	10723949	2000
31	Serum thrombopoietin levels in thrombocytopenic and non-thrombocytopenic patients with human immunodeficiency virus (HIV-1) infection. ⁵⁴ ⁶¹	Espanol I...Pujol-Moix N	10530413	1999
32	Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. ⁵⁴ ⁶¹	Sato S...Tanaka K	10081639	1999
33	Recurrent hepatosplenomegaly and peripheral blood cytopenia, persistent Epstein-Barr virus infection and central nervous system manifestation in a patient with lymphadenopathy and low serum uric acid. ⁵⁴ ⁶¹	Sugita K...Furukawa T	9745782	1998
34	Successful treatment of aplastic anemia with G-CSF and high dose erythropoietin. ⁵⁴ ⁶¹	Nishii K...Shiku H	9669693	1998
35	Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. ⁵⁴ ⁶¹	Ida H...Eto Y	9541479	1998
36	T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. ⁵⁴ ⁶¹	Mavroudis DA...Barrett AJ	9535034	1998
37	Crescentic glomerulonephritis accompanied by myeloperoxidase-antineutrophil cytoplasmic antibodies in a patient having myelodysplastic syndrome with trisomy 7. ⁵⁴ ⁶¹	Komatsuda A...Chubachi A	9469507	1998
38	Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. ⁵⁴ ⁶¹	Neelis KJ...Wagemaker G	9293906	1997
39	Growth factor administration following autologous peripheral blood progenitor cell transplantation. ⁵⁴ ⁶¹	Pierelli L...Leone G	9373197	1997
40	Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. ⁵⁴ ⁶¹	Neelis KJ...Wagemaker G	9207438	1997
41	Copper deficiency with pancytopenia due to enteral nutrition through jejunostomy. ⁵⁴ ⁶¹	Camblor M...Garcia P	16844585	1997
42	Granulocyte-colony stimulating factor in the treatment of colchicine poisoning. ⁵⁴ ⁶¹	Critchley JA...Goh VK	9154449	1997
43	Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. ⁵⁴ ⁶¹	Edelman MJ...Meadows I	9092691	1997
44	[Allopurinol induced pancytopenia in a patient with myeloproliferative disorder]. ⁵⁴ ⁶¹	Shinagawa A...Abe T	9028164	1997
45	Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease. ⁵⁴ ⁶¹	Notario A...Mazzucchelli I	8767533	1996
46	Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis. ⁵⁴ ⁶¹	Bourantas KL...Seferiadis K	8701705	1996
47	Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. ⁵⁴ ⁶¹	Maze R...Samson L	8552605	1996
48	[The Recormon (recombinant erythropoietin) treatment of a patient with pancytopenia of the blood and chronic viral hepatitis C]. ⁵⁴ ⁶¹	Lukina EA...Frank GA	9019832	1996
49	Trilineage response to granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome. ⁵⁴ ⁶¹	Perugini O...Nalli G	7545637	1995
50	Early recovery of host-derived hematopoiesis in marrow transplant recipients conditioned with high-dose busulfan and cyclophosphamide. ⁵⁴ ⁶¹	Yamaguchi M...Matsuda T	7670408	1995

Sources

Genes for Pancytopenia

Genes related to Pancytopenia (5 elite genes):

(show top 50) (show all 74)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	DNAJC21	DnaJ Heat Shock Protein Family (Hsp40) Member C21	Protein Coding	419.42	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Variants (show sections)
2	TP53	Tumor Protein P53	Protein Coding	412.4	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
3	FOXP3	Forkhead Box P3	Protein Coding	411.79	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
4	TTR	Transthyretin	Protein Coding	410.28	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
5	CPT2	Carnitine Palmitoyltransferase 2	Protein Coding	406.66	Pathogenic ⁶ GeneCards inferred via : Variants (show sections)
6	SAMD9L	Sterile Alpha Motif Domain Containing 9 Like	Protein Coding	40.92	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
7	CSF3	Colony Stimulating Factor 3	Protein Coding	24.14	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	1384817 17039083 11680980 (more) 9535034 17118765 18541787 1378668 7545637 8767533 9154449 20094735 7670408 7683451 9293906 7680523 11361215 9669693 9028164 7519041 20190483 10081639 9092691 7536347 12858207 7504385 12609794 17505274
8	DHFR	Dihydrofolate Reductase	Protein Coding	22.12	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Disorders Publications (show sections)	2353761
9	TPMT	Thiopurine S-Methyltransferase	Protein Coding	21.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	11037857 12172211 12454589 (more) 16995868 18520612 12477776
10	TERT	Telomerase Reverse Transcriptase	Protein Coding	20.48	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
11	EPO	Erythropoietin	Protein Coding	20.4	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	1625496 8244908 17118765 (more) 10081639 9028164 9019832 8701705 9469507 9669693 1545564
12	DKC1	Dyskerin Pseudouridine Synthase 1	Protein Coding	20.03	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	11491307
13	CSF2	Colony Stimulating Factor 2	Protein Coding	18.3	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	7680523 8283365
14	CSF1	Colony Stimulating Factor 1	Protein Coding	15.78	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	1625496 8460579 10081639
15	MPL	MPL Proto-Oncogene, Thrombopoietin Receptor	Protein Coding	14.49	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	20125166 16470591 15958695 (more) 11133753
16	THPO	Thrombopoietin	Protein Coding	14.18	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11895799 9207438 12694260 (more) 10530413 19630808 9293906
17	CP	Ceruloplasmin	Protein Coding	14.02	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16844585
18	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	13.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	19037596 8552605
19	SH2D1A	SH2 Domain Containing 1A	Protein Coding	13.37	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
20	IFNG	Interferon Gamma	Protein Coding	13.07	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
21	IL3	Interleukin 3	Protein Coding	12.84	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	8273363 2048562 8292809 (more) 9373197 17312671
22	CBLIF	Cobalamin Binding Intrinsic Factor	Protein Coding	12.81	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	IL6	Interleukin 6	Protein Coding	12.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	RAB27A	RAB27A, Member RAS Oncogene Family	Protein Coding	12.57	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
25	CD68	CD68 Molecule	Protein Coding	12.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
26	LIG4	DNA Ligase 4	Protein Coding	12.5	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
27	TCN2	Transcobalamin 2	Protein Coding	12.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	2309761
28	XIAP	X-Linked Inhibitor Of Apoptosis	Protein Coding	12.38	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
29	CD55	CD55 Molecule (Cromer Blood Group)	Protein Coding	12.24	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	15103939
30	MECOM	MDS1 And EVI1 Complex Locus	Protein Coding	12.1	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
31	SAMD9	Sterile Alpha Motif Domain Containing 9	Protein Coding	11.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
32	ACE	Angiotensin I Converting Enzyme	Protein Coding	11.63	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
33	RUNX1	RUNX Family Transcription Factor 1	Protein Coding	11.47	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
34	ITK	IL2 Inducible T Cell Kinase	Protein Coding	11.43	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
35	IKZF1	IKAROS Family Zinc Finger 1	Protein Coding	11.39	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
36	TALDO1	Transaldolase 1	Protein Coding	11.29	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
37	G6PC3	Glucose-6-Phosphatase Catalytic Subunit 3	Protein Coding	11.08	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
38	GBA	Glucosylceramidase Beta	Protein Coding	10.83	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	9541479
39	MCEE	Methylmalonyl-CoA Epimerase	Protein Coding	10.59	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
40	ITPA	Inosine Triphosphatase	Protein Coding	10.5	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
41	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	10.49	DISEASES inferred ¹⁵ ¹⁵
42	MPIG6B	Megakaryocyte And Platelet Inhibitory Receptor G6b	Protein Coding	10.45	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
43	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	9.94	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	10723949 20379108 17313078 (more) 15387287
44	TBXAS1	Thromboxane A Synthase 1	Protein Coding	9.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
45	KMT2A	Lysine Methyltransferase 2A	Protein Coding	9.64	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	11920839
46	HP	Haptoglobin	Protein Coding	9.58	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	9745782 7967061
47	CD34	CD34 Molecule	Protein Coding	7.67	DISEASES inferred ¹⁵
48	CD4	CD4 Molecule	Protein Coding	7.36	DISEASES inferred ¹⁵
49	CD40LG	CD40 Ligand	Protein Coding	7.34	DISEASES inferred ¹⁵
50	CD33	CD33 Molecule	Protein Coding	7.3	DISEASES inferred ¹⁵

Sources

Variations for Pancytopenia

ClinVar genetic disease variations for Pancytopenia:

⁶ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	CPT2	NM_000098.3(CPT2):c.149C>A (p.Pro50His)	SNV	Pathogenic	8954	rs28936375	1:53662764-53662764	1:53197092-53197092
2	TP53	NM_000546.5(TP53):c.742C>T (p.Arg248Trp)	SNV	Pathogenic	12347	rs121912651	17:7577539-7577539	17:7674221-7674221
3	TTR	NM_000371.3(TTR):c.424G>A (p.Val142Ile)	SNV	Pathogenic	13426	rs76992529	18:29178618-29178618	18:31598655-31598655
4	FOXP3	NM_014009.3(FOXP3):c.1190G>A (p.Arg397Gln)	SNV	Pathogenic	379222	rs1057520529	X:49107901-49107901	X:49251440-49251440
5	DNAJC21	NM_001012339.3(DNAJC21):c.544C>T (p.Arg182Ter)	SNV	Pathogenic	598950	rs771063992	5:34937536-34937536	5:34937431-34937431
6	RUNX1	NM_001754.4(RUNX1):c.502G>T (p.Gly168Ter)	SNV	Likely pathogenic	627081		21:36252860-36252860	21:34880563-34880563
7	SOX3	NM_005634.2(SOX3):c.735_737dup (p.Ala248dup)	duplication	Conflicting interpretations of pathogenicity	95305	rs398124211	X:139586488-139586489	X:140504323-140504324

Sources

Expression for Pancytopenia

Search GEO for disease gene expression data for Pancytopenia.

Sources

Pathways for Pancytopenia

Pathways related to Pancytopenia according to GeneCards Suite gene sharing:

(show all 17)

#	Super pathways	Score	Top Affiliating Genes
1	Folate Metabolism ¹ Show member pathways Selenium Micronutrient Network ¹ thioredoxin pathway ¹ Vitamin B12 Metabolism ¹	12.13	TP53 IFNG DHFR CSF1
2	Immune response IFN alpha/beta signaling pathway ²² Show member pathways Cytokine Network ⁶³ Interferon alpha/beta signaling ⁶⁵ Regulation of IFNA signaling ⁶⁵	11.98	TP53 THPO TERT IFNG DKC1
3	JAK-STAT signaling pathway (KEGG) ³⁶ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁵ Jak/STAT Signaling Pathway ⁶⁴	11.8	THPO MPL IFNG EPO CSF3 CSF2
4	Rheumatoid arthritis ³⁶	11.71	IFNG CSF2 CSF1
5	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.7	FOXP3 CSF3 CSF2
6	Hematopoietic cell lineage ³⁶	11.65	THPO EPO CSF3 CSF2 CSF1
7	Glucocorticoid receptor regulatory network ¹	11.63	TP53 IFNG CSF2
8	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ¹	11.58	IFNG FOXP3 CSF2
9	Dendritic Cells Developmental Lineage Pathway ⁶⁴	11.56	IFNG CSF2 CSF1
10	Regulation of Telomerase ¹	11.47	TERT IFNG DKC1
11	HIF-1-alpha transcription factor network ¹	11.45	TERT EPO CP
12	Lung fibrosis ¹	11.41	TERT CSF3 CSF2
13	Hematopoietic Stem Cell Differentiation ¹	11.3	EPO CSF3 CSF2 CSF1
14	Interleukin-10 signaling ⁶⁵	11.27	CSF3 CSF2 CSF1
15	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁴	11.23	THPO MPL IFNG EPO CSF3 CSF2
16	Cytokines and Inflammatory Response ¹	10.92	IFNG CSF3 CSF2 CSF1
17	Development of pulmonary dendritic cells and macrophage subsets ¹	10.66	CSF2 CSF1

Sources

GO Terms for Pancytopenia

Cellular components related to Pancytopenia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.23	TTR THPO IFNG EPO CSF3 CSF2

Biological processes related to Pancytopenia according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.81	TP53 TERT IFNG FOXP3
2	positive regulation of gene expression	GO:0010628	9.77	TP53 IFNG FOXP3 CSF2 CSF1
3	cell proliferation	GO:0008283	9.73	TP53 THPO EPO CSF1
4	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.58	IFNG EPO CSF2
5	response to hyperoxia	GO:0055093	9.52	TP53 EPO
6	negative regulation of neuron death	GO:1901215	9.5	EPO CSF3 CSF1
7	negative regulation of interleukin-17 production	GO:0032700	9.49	IFNG FOXP3
8	replicative senescence	GO:0090399	9.48	TP53 TERT
9	response to salt stress	GO:0009651	9.46	TP53 EPO
10	positive regulation of cell proliferation	GO:0008284	9.43	THPO IFNG EPO CSF3 CSF2 CSF1
11	thrombopoietin-mediated signaling pathway	GO:0038163	9.26	THPO MPL
12	positive regulation of interleukin-23 production	GO:0032747	9.16	IFNG CSF2
13	cytokine-mediated signaling pathway	GO:0019221	9.02	TP53 MPL CSF3 CSF2 CSF1

Molecular functions related to Pancytopenia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth factor activity	GO:0008083	9.26	THPO CSF3 CSF2 CSF1
2	telomerase activity	GO:0003720	9.16	TERT DKC1
3	cytokine activity	GO:0005125	9.1	THPO IFNG EPO CSF3 CSF2 CSF1

Sources

Sources for Pancytopenia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia